CXCR4 and hepatocellular carcinoma: In contrast, CRISPR/Cas9-mediated knockout of CXCR4 inhibits proliferation, migration, and invasion of HepG2 cells while also reversing epithelial-mesenchymal transition (EMT), increasing HCC chemosensitivity, and reducing its malignancy in vitro and in vivo [72].